Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
SAN DIEGO, Jan. 26 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) reported today that its Cardium Biologics division provided an update on plans for the continuing commercial...
SAN DIEGO, Jan. 5 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced plans to launch a new premium advanced skin care product line to promote foot health and comfort...
SAN DIEGO, Jan. 4 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) reported that it received notification from the staff of the company's current listing exchange indicating that...
SAN DIEGO, Dec. 16 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today reported on recent clinical findings published in the December issue of Diabetes Care showing an increase...
SAN DIEGO, Dec. 14 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) announced a presentation titled, "Phase 2b Study of GAM501 (Ad5PDGF-B/Collagen) in the Treatment of Diabetic...
SAN DIEGO, Dec. 3 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) announced today that its wholly-owned subsidiary, Tissue Repair Company, submitted a 510(k) premarket...
SAN DIEGO, Nov. 10 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today reported its financial results for its third quarter ended September 30, 2009, and on recent developments...
SAN DIEGO, Nov. 2 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced plans to submit a 510(k) premarket notification with the U.S. Food and Drug Administration (FDA...
SAN DIEGO, Oct. 20 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced that it has completed its previously announced $6.0 million registered direct offering of...
SAN DIEGO, Oct. 15 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced a registered direct offering of common stock to selected investors for aggregate gross proceeds...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 15 | 2.88461538462 | 520 | 540 | 520 | 15 | 535 | DE |
| 4 | 35 | 7 | 500 | 540 | 500 | 11 | 512.85046729 | DE |
| 12 | -10 | -1.83486238532 | 545 | 550 | 480 | 14 | 511.92082111 | DE |
| 26 | 37 | 7.4297188755 | 498 | 570 | 480 | 11 | 517.75862069 | DE |
| 52 | 0 | 0 | 535 | 570 | 480 | 10 | 513.72154116 | DE |
| 156 | 0 | 0 | 535 | 570 | 480 | 10 | 513.72154116 | DE |
| 260 | 0 | 0 | 535 | 570 | 480 | 10 | 513.72154116 | DE |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
